Effects of teplizumab on development of type 1 diabetes

Shown are Kaplan-Meier estimates of the proportion of participants in whom clinical diabetes was not diagnosed. The overall hazard ratio was 0.41 (95% CI 0.22-0.78; two-sided p = 0.006 by adjusted Cox proportional-hazards model). The median time to diagnosis of type 1 diabetes was 48.4 months in the teplizumab group and 24.4 months in the placebo group. The numbers of participants with or without a diagnosis of clinical type 1 diabetes (upper right) represent data at the conclusion of the trial. Tick marks indicate censored data.